Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

HALO Diagnostics

Explore full profile

Precision diagnostics and personalized care to fight deadly diseases with advanced imaging and genetic tests

Menlo Park, United StatesFounded 2019Biotech & Life Sciences
Valuation $0–100M Latest valuation · 2021
Headcount 100–500 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for HALO Diagnostics and the history behind them.

About HALO Diagnostics

HALO Diagnostics is a cutting-edge healthcare startup specializing in precision diagnostics. The company operates state-of-the-art diagnostic centers where all tests are performed under one roof, ensuring a seamless and efficient patient experience. HALO Diagnostics focuses on early detection and personalized care for five critical health areas: breast health, cardiac health, prostate health, lung cancer, and brain injuries.

Read full description

The company serves a diverse range of clients, primarily individuals who are at risk for these serious health conditions or are seeking early detection and personalized treatment plans. HALO Diagnostics operates in the healthcare market, specifically within the niche of precision diagnostics and advanced imaging.

HALO Diagnostics' business model revolves around providing comprehensive diagnostic services. They make money by offering a variety of tests and imaging services, such as breast screenings, cardiac imaging, prostate cancer diagnostics, lung cancer screenings, and brain injury assessments. These services are often combined with genetic tests and personalized treatment plans, enhancing the overall value proposition for patients.

The company is innovating in the field of healthcare by using advanced imaging technologies and sophisticated diagnostic tools. For instance, their cardiac imaging can detect plaque in arteries, helping to determine the best treatment options. Similarly, their prostate care program combines diagnostics, genetic tests, and treatments to improve the quality of life and reduce prostate cancer deaths. Their lung cancer screenings have been shown to reduce the risk of death by 20%, and their brain injury imaging helps in quick and accurate treatment.

In summary, HALO Diagnostics is setting new standards in precision diagnostics and personalized healthcare, aiming to save lives through early disease detection and individualized care plans.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2019
Headquarters
Menlo Park, United States
Employees
138
Open positions
18
Dealroom signal
60.8/100
Industry
Health
Sub-industry
BioTechnology, Medical Devices
Sector
Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
b2b

Latest news

Press, funding announcements and product moves mentioning HALO Diagnostics.

See all news

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES AEquity / VC Mar 2021 $19M $76M Anne Wojcicki · Ronnie Lott · Bob Reed · Robert Ciardi
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

HALO Diagnostics website traffic

Latest recorded traffic for HALO Diagnostics is 28K monthly website visits, up 154.5% over the last three months. HALO Diagnostics's team declined 2.1% over the past year.

Latest monthly visits28K 3-month web change+154.5% 1-year team growth-2.1%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investors

10 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A8 investors entered at this stage

  • Zola Global
  • Anne Wojcicki
  • Ronnie Lott
  • Bob Reed
  • Robert Ciardi
  • Fred Moll
  • Jim Pallotta
  • Stephen Pomeranz

Other known investors2 additional known investors

  • Angel Kelchev
  • Todd Meyerrose
Team profiled 19 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 5 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇺🇸 United States83%
🇧🇬 Bulgaria16%
🇨🇦 Canada1.1%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about HALO Diagnostics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See HALO Diagnostics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.